688302 海创药业
已收盘 02-26 15:00:00
资讯
新帖
简况
每周股票复盘：海创药业（688302）获GMP认证生产扩容
证券之星 · 02-08
每周股票复盘：海创药业（688302）获GMP认证生产扩容
股市必读：海创药业（688302）预计2025年全年扣除后营业收入:1,900万元至2,200万元
证券之星 · 02-02
股市必读：海创药业（688302）预计2025年全年扣除后营业收入:1,900万元至2,200万元
每周股票复盘：海创药业（688302）募投项目延期至2026年底
证券之星 · 2025-12-28
每周股票复盘：海创药业（688302）募投项目延期至2026年底
储能行业点评报告：全球首款锂钠协同储能方案发布，AIDC配储增量可期
华龙证券 · 2025-12-22
储能行业点评报告：全球首款锂钠协同储能方案发布，AIDC配储增量可期
12月11日海创药业涨6.32%，鹏华医药科技股票A基金重仓该股
证券之星 · 2025-12-11
12月11日海创药业涨6.32%，鹏华医药科技股票A基金重仓该股
创新药概念局部活跃 海创药业涨超11%
每日经济新闻 · 2025-12-11
创新药概念局部活跃 海创药业涨超11%
海创药业（688302）披露拟变更公司住所及修订公司章程，12月8日股价下跌0.94%
证券之星 · 2025-12-08
海创药业（688302）披露拟变更公司住所及修订公司章程，12月8日股价下跌0.94%
海创药业(688302.SH)：氘恩扎鲁胺软胶囊被纳入2025年国家医保药品目录
智通财经 · 2025-12-07
海创药业(688302.SH)：氘恩扎鲁胺软胶囊被纳入2025年国家医保药品目录
海创药业(688302.SH)：口服PROTAC药物HP518片联合抗肿瘤药物治疗晚期前列腺癌获批临床试验
智通财经 · 2025-11-24
海创药业(688302.SH)：口服PROTAC药物HP518片联合抗肿瘤药物治疗晚期前列腺癌获批临床试验
每周股票复盘：海创药业（688302）将召开2025年第三季度业绩说明会
证券之星 · 2025-11-09
每周股票复盘：海创药业（688302）将召开2025年第三季度业绩说明会
海创药业（688302）披露召开2025年第三季度业绩说明会公告，11月06日股价下跌2.17%
证券之星 · 2025-11-06
海创药业（688302）披露召开2025年第三季度业绩说明会公告，11月06日股价下跌2.17%
海创药业(688302.SH)：治疗代谢相关脂肪性肝炎(MASH)药物HP515临床II期试验完成首批参与者入组
智通财经 · 2025-11-04
海创药业(688302.SH)：治疗代谢相关脂肪性肝炎(MASH)药物HP515临床II期试验完成首批参与者入组
海创药业（688302）披露2025年第三季度报告，10月31日股价下跌2.48%
证券之星 · 2025-10-31
海创药业（688302）披露2025年第三季度报告，10月31日股价下跌2.48%
图解海创药业三季报：第三季度单季净利润同比增长30.50%
证券之星 · 2025-10-31
图解海创药业三季报：第三季度单季净利润同比增长30.50%
海创药业（688302）披露2025年第一次临时股东大会通知，10月14日股价下跌3.25%
证券之星 · 2025-10-14
海创药业（688302）披露2025年第一次临时股东大会通知，10月14日股价下跌3.25%
海创药业（688302）1750.05万股限售股将于10月13日解禁，占总股本17.67%
证券之星 · 2025-10-13
海创药业（688302）1750.05万股限售股将于10月13日解禁，占总股本17.67%
每周股票复盘：海创药业（688302）部分限售股10月13日上市
证券之星 · 2025-09-28
每周股票复盘：海创药业（688302）部分限售股10月13日上市
海创药业（688302）披露首次公开发行部分限售股上市流通公告，9月26日股价下跌4.0%
证券之星 · 2025-09-26
海创药业（688302）披露首次公开发行部分限售股上市流通公告，9月26日股价下跌4.0%
每周股票复盘：海创药业（688302）将举行2025年半年度业绩说明会
证券之星 · 2025-09-14
每周股票复盘：海创药业（688302）将举行2025年半年度业绩说明会
每周股票复盘：海创药业（688302）氘恩扎鲁胺上市助营收增11899%
证券之星 · 2025-09-07
每周股票复盘：海创药业（688302）氘恩扎鲁胺上市助营收增11899%
暂无数据
公司概况
公司名称：
海创药业股份有限公司
所属行业：
医药制造业
上市日期：
2022-04-12
主营业务：
海创药业股份有限公司的主营业务是肿瘤、代谢性疾病等重大治疗领域的创新药物研发。公司的主要产品是HC-1119、HP518（PROTAC）、HP568（PROTAC）、HP537、HP560、HP501、HP515。公司荣获“2024年成都市企业技术中心”，“2024中国医药研发排行榜化药榜单前100强”，“成都市高新区“金熊猫未来星”·企业关键核心技术奖”等荣誉及称号。
发行价格：
42.92
{"stockData":{"symbol":"688302","market":"SH","secType":"STK","nameCN":"海创药业","latestPrice":44,"timestamp":1772089200000,"preClose":45.18,"halted":0,"volume":1420549,"delay":0,"changeRate":-0.0261,"floatShares":99015600,"shares":99015600,"eps":-1.4601,"marketStatus":"已收盘","change":-1.18,"latestTime":"02-26 15:00:00","open":45.3,"high":45.38,"low":43.79,"amount":62757900,"amplitude":0.0352,"askPrice":44,"askSize":5,"bidPrice":43.91,"bidSize":2,"shortable":0,"etf":0,"ttmEps":-1.4601,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772155800000},"marketStatusCode":5,"adr":0,"adjPreClose":45.18,"symbolType":"stock_kcb","openAndCloseTimeList":[[1772069400000,1772076600000],[1772082000000,1772089200000]],"highLimit":49.7,"lowLimit":40.66,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":99015598,"isCdr":false,"pbRate":3.96,"roa":"--","roe":"--","epsLYR":-2.01,"committee":-0.847059,"marketValue":4357000000,"turnoverRate":0.0143,"status":1,"afterMarket":{"amount":0,"volume":0,"close":44,"buyVolume":0,"sellVolume":0,"time":1772091237558,"indexStatus":"已收盘 02-26 15:30:00","preClose":45.18},"floatMarketCap":4357000000},"requestUrl":"/m/hq/s/688302/tweets","defaultTab":"tweets","newsList":[{"id":"2609185526","title":"每周股票复盘：海创药业（688302）获GMP认证生产扩容","url":"https://stock-news.laohu8.com/highlight/detail?id=2609185526","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609185526?lang=zh_cn&edition=full","pubTime":"2026-02-08 03:00","pubTimestamp":1770490837,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘，海创药业报收于45.83元，较上周的46.0元下跌0.37%。本周，海创药业2月6日盘中最高价报46.67元。本周关注点公司公告汇总：海创药业软胶囊剂生产线通过GMP符合性检查，生产范围新增抗肿瘤药。此次变更有助于公司优化生产结构，提升核心竞争力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800001052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2608092881","title":"股市必读：海创药业（688302）预计2025年全年扣除后营业收入:1,900万元至2,200万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608092881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608092881?lang=zh_cn&edition=full","pubTime":"2026-02-02 05:06","pubTimestamp":1769979978,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，海创药业报收于46.0元，下跌0.28%，换手率1.24%，成交量1.23万手，成交额5671.17万元。业绩披露要点业绩预告海创药业发布业绩预告，预计2025年全年归属净利润亏损1.25亿元至1.5亿元；扣非后净利润亏损1.55亿元至1.85亿元；营业收入预计为1900万元至2200万元；扣除后营业收入为1900万元至2200万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200002398.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302"],"gpt_icon":0},{"id":"2594424402","title":"每周股票复盘：海创药业（688302）募投项目延期至2026年底","url":"https://stock-news.laohu8.com/highlight/detail?id=2594424402","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594424402?lang=zh_cn&edition=full","pubTime":"2025-12-28 04:17","pubTimestamp":1766866628,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，海创药业报收于50.29元，较上周的52.44元下跌4.1%。本周，海创药业12月22日盘中最高价报53.15元。会议审议通过《关于审议豁免本次会议通知时限的议案》和《关于首次公开发行股票部分募投项目延期的议案》。董事会认为项目延期系基于实际情况的审慎决定，程序合规，未损害股东利益。“研发生产基地建设项目”原定于2025年12月31日达到预定可使用状态，现调整至2026年12月31日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800001053.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2593482191","title":"储能行业点评报告：全球首款锂钠协同储能方案发布，AIDC配储增量可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2593482191","media":"华龙证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593482191?lang=zh_cn&edition=full","pubTime":"2025-12-22 20:07","pubTimestamp":1766405252,"startTime":"0","endTime":"0","summary":"全球首款锂钠协同储能方案发布。AIDC配储渗透率及配储时长有望提升，我们测算2030年AIDC配储需求或超100gwh。我们认为2026年储能市场或延续高速增长态势，AIDC配套储能系统有望迎来规模化部署高峰期，大储市场需求正向“4小时及更长时长”迁移。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222200743a6c167ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222200743a6c167ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0880133367.SGD","300014","688472","LU0067412154.USD","LU1152091168.USD","LU1993786604.SGD","BK1116","688599","300274","BK1610","LU1960683339.HKD","03750","LU1152091754.HKD","LU1008478684.HKD","688302","300750","002150","LU1807302812.USD"],"gpt_icon":1},{"id":"2590560774","title":"12月11日海创药业涨6.32%，鹏华医药科技股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2590560774","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590560774?lang=zh_cn&edition=full","pubTime":"2025-12-11 15:33","pubTimestamp":1765438438,"startTime":"0","endTime":"0","summary":"证券之星消息，12月11日海创药业涨6.32%创60日新高，收盘报57.0元，换手率7.01%，成交量6.94万手，成交额3.96亿元。该股为创新药、医药概念热股。重仓海创药业的公募基金请见下表：根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为鹏华基金的鹏华医药科技股票A。鹏华医药科技股票A目前规模为19.21亿元，最新净值1.7336，较上一交易日上涨0.14%，近一年上涨57.61%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100019510.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","BK1161","09939","BK1515","159938","688302"],"gpt_icon":0},{"id":"2590566181","title":"创新药概念局部活跃 海创药业涨超11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590566181","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590566181?lang=zh_cn&edition=full","pubTime":"2025-12-11 11:09","pubTimestamp":1765422540,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月11日，创新药概念局部活跃，海创药业涨超11%，前沿生物涨超8%，重药控股此前涨停，悦康药业、热景生物、回盛生物、众生药业跟涨。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-11/doc-inhakwan8087335.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-11/doc-inhakwan8087335.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","159992","BK1161","BK1574","688302","06978"],"gpt_icon":0},{"id":"2589393943","title":"海创药业（688302）披露拟变更公司住所及修订公司章程，12月8日股价下跌0.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589393943","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589393943?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:52","pubTimestamp":1765187571,"startTime":"0","endTime":"0","summary":"截至2025年12月8日收盘，海创药业报收于47.51元，较前一交易日下跌0.94%，最新总市值为47.04亿元。该股当日开盘49.45元，最高49.78元，最低47.45元，成交额达7010.09万元，换手率为1.46%。根据近日发布的公告，海创药业拟变更公司住所，由四川省成都市高新区科园南路5号蓉药大厦1栋4层附2、3号变更为四川省成都市双流区凤凰路558号。为配合上述事项，公司将相应修订《公司章程》第五条关于住所的条款。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120800022657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2589321879","title":"海创药业(688302.SH)：氘恩扎鲁胺软胶囊被纳入2025年国家医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589321879","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589321879?lang=zh_cn&edition=full","pubTime":"2025-12-07 16:10","pubTimestamp":1765095050,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海创药业(688302.SH)发布公告，2025年12月7日，国家医保局、人力资源社会保障部公布了《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(以下简称“国家医保药品目录”)，公司自主研发的氘恩扎鲁胺软胶囊通过国家医保谈判，首次被纳入国家医保药品目录，该目录将于2026年1月1日起执行。氘恩扎鲁胺软胶囊(曾用名：HC-1119软胶囊)是公司自主研发的、用于治疗转移性去势抵抗性前列腺癌(mCRPC)的1类新药，是第二代雄激素受体(AR)抑制剂，获得国家重大新药创制科技重大专项支持。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378478.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海创药业(688302.SH)：氘恩扎鲁胺软胶囊被纳入2025年国家医保药品目录","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2585126457","title":"海创药业(688302.SH)：口服PROTAC药物HP518片联合抗肿瘤药物治疗晚期前列腺癌获批临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2585126457","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585126457?lang=zh_cn&edition=full","pubTime":"2025-11-24 17:10","pubTimestamp":1763975404,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海创药业 发布公告，近日，公司收到中国国家药品监督管理局药品审评中心核准签发的《药物临床试验批准通知书》，同意HP518片联合抗肿瘤药物开展用于治疗晚期前列腺癌的Ⅰb/Ⅱ期临床试验。截至目前，HP518片已分别于中国、澳大利亚和美国三个国家获批开展用于晚期前列腺癌的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1372746.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"海创药业(688302.SH)：口服PROTAC药物HP518片联合抗肿瘤药物治疗晚期前列腺癌获批临床试验","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2582641198","title":"每周股票复盘：海创药业（688302）将召开2025年第三季度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2582641198","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582641198?lang=zh_cn&edition=full","pubTime":"2025-11-09 05:18","pubTimestamp":1762636699,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，海创药业报收于47.5元，较上周的52.25元下跌9.09%。本周，海创药业11月3日盘中最高价报52.79元。海创药业当前最新总市值47.03亿元，在化学制药板块市值排名111/151，在两市A股市值排名3508/5166。本周关注点公司公告汇总：海创药业将于2025年11月14日召开第三季度业绩说明会，介绍经营成果及财务状况。投资者可于2025年11月7日至11月13日16:00前通过上证路演中心网站或公司邮箱ir@hinovapharma.com提问，公司将在说明会上对普遍关注的问题进行回应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900001900.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2581709121","title":"海创药业（688302）披露召开2025年第三季度业绩说明会公告，11月06日股价下跌2.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2581709121","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581709121?lang=zh_cn&edition=full","pubTime":"2025-11-06 22:23","pubTimestamp":1762439001,"startTime":"0","endTime":"0","summary":"截至2025年11月6日收盘，海创药业报收于47.72元，较前一交易日下跌2.17%，最新总市值为47.25亿元。该股当日开盘48.99元，最高49.12元，最低47.65元，成交额达6876.37万元，换手率为1.44%。近日，海创药业发布公告称，公司将于2025年11月14日14:00-15:00通过上证路演中心网络文字互动方式召开2025年第三季度业绩说明会，介绍公司2025年第三季度经营成果及财务状况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600038212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2580200041","title":"海创药业(688302.SH)：治疗代谢相关脂肪性肝炎(MASH)药物HP515临床II期试验完成首批参与者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2580200041","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580200041?lang=zh_cn&edition=full","pubTime":"2025-11-04 16:25","pubTimestamp":1762244730,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海创药业 发布公告，公司自主研发的拟用于治疗代谢相关脂肪性肝炎的HP515临床II期试验于近日完成首批参与者入组。截至公告披露日，国内无同类靶点产品获批上市。HP515于2024年8月获得中国国家药品监督管理局批准用于代谢性脂肪性肝炎，并于2024年9月获得美国食品药品监督管理局的批准用于代谢性脂肪性肝炎。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1364997.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2579454669","title":"海创药业（688302）披露2025年第三季度报告，10月31日股价下跌2.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579454669","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579454669?lang=zh_cn&edition=full","pubTime":"2025-10-31 17:53","pubTimestamp":1761904399,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，海创药业报收于52.25元，较前一交易日下跌2.48%，最新总市值为51.74亿元。该股当日开盘50.5元，最高52.25元，最低49.2元，成交额达1.71亿元，换手率为3.4%。近日，海创药业发布2025年第三季度报告，披露了公司主要财务数据及股东信息。根据公告，2025年前三季度，公司实现营业收入23,351,806.02元，较上年同期增长21,180.28%；归属于上市公司股东的净利润为-99,147,164.40元，亏损同比扩大。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100038331.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2579175292","title":"图解海创药业三季报：第三季度单季净利润同比增长30.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579175292","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579175292?lang=zh_cn&edition=full","pubTime":"2025-10-31 02:47","pubTimestamp":1761850044,"startTime":"0","endTime":"0","summary":"证券之星消息，海创药业2025年三季报显示，前三季度公司主营收入2335.18万元，同比上升21180.28%；归母净利润-9914.72万元，同比上升35.65%；扣非净利润-1.2亿元，同比上升28.35%；其中2025年第三季度，公司单季度主营收入1018.47万元，单季度归母净利润-3729.4万元，同比上升30.5%；单季度扣非净利润-4689.91万元，同比上升18.21%；负债率19.24%，投资收益305.55万元，财务费用-521.17万元，毛利率99.57%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100003042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302"],"gpt_icon":0},{"id":"2575214627","title":"海创药业（688302）披露2025年第一次临时股东大会通知，10月14日股价下跌3.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575214627","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575214627?lang=zh_cn&edition=full","pubTime":"2025-10-14 22:43","pubTimestamp":1760452995,"startTime":"0","endTime":"0","summary":"截至2025年10月14日收盘，海创药业报收于48.86元，较前一交易日下跌3.25%，最新总市值为48.38亿元。近日，海创药业发布公告称，公司将于2025年10月30日14:00在四川省成都市高新区科园南路5号蓉药大厦1栋4层公司会议室召开2025年第一次临时股东大会，会议将采用现场投票与网络投票相结合的方式进行。股权登记日为2025年10月27日。现场参会股东需于2025年10月28日前通过邮件方式完成登记。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101400065631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2575449370","title":"海创药业（688302）1750.05万股限售股将于10月13日解禁，占总股本17.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2575449370","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575449370?lang=zh_cn&edition=full","pubTime":"2025-10-13 08:02","pubTimestamp":1760313752,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，海创药业于10月13日将有1750.05万股限售股份解禁，为公司追加承诺限售股份上市流通，占公司总股本17.67%。具体如下图所示：本次解禁涉及股东明细见下表：海创药业财务数据及主营业务：海创药业2025年中报显示，公司主营收入1316.71万元，同比上升11899.08%；归母净利润-6185.32万元，同比上升38.4%；扣非净利润-7300.56万元，同比上升33.63%；负债率18.32%，投资收益184.34万元，财务费用-396.48万元，毛利率99.52%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300002403.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2570894876","title":"每周股票复盘：海创药业（688302）部分限售股10月13日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2570894876","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570894876?lang=zh_cn&edition=full","pubTime":"2025-09-28 03:36","pubTimestamp":1759001773,"startTime":"0","endTime":"0","summary":"截至2025年9月26日收盘，海创药业报收于52.78元，较上周的53.63元下跌1.58%。本周，海创药业9月24日盘中最高价报58.1元。公司公告汇总海创药业首次公开发行部分限售股将于2025年10月13日上市流通，数量为17,500,478股，占公司总股本的17.6745%。涉及股东3名，分别为Affinitis Group LLC、陈元伦和周雯，限售期为自公司股票上市之日起42个月。上述股东已履行相关股份锁定承诺，本次上市流通后，其剩余限售股数量均为0。保荐机构中信证券对本次限售股上市流通事项无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092800000842.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302","BK0239"],"gpt_icon":0},{"id":"2570882148","title":"海创药业（688302）披露首次公开发行部分限售股上市流通公告，9月26日股价下跌4.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2570882148","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570882148?lang=zh_cn&edition=full","pubTime":"2025-09-26 22:33","pubTimestamp":1758897214,"startTime":"0","endTime":"0","summary":"截至2025年9月26日收盘，海创药业报收于52.78元，较前一交易日下跌4.0%，最新总市值为52.26亿元。近日，海创药业发布首次公开发行部分限售股上市流通公告。本次限售股涉及股东3名，分别为Affinitis Group LLC、陈元伦和周雯，限售期为自公司股票上市之日起42个月。本次限售股上市后，该3名股东剩余限售股数量均为0。保荐机构中信证券对本次限售股上市流通无异议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092600039248.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2567361401","title":"每周股票复盘：海创药业（688302）将举行2025年半年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2567361401","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567361401?lang=zh_cn&edition=full","pubTime":"2025-09-14 05:03","pubTimestamp":1757797394,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，海创药业报收于56.48元，较上周的58.28元下跌3.09%。本周，海创药业9月8日盘中最高价报59.23元。本周关注点公司公告汇总：海创药业将于2025年09月16日举行2025年半年度科创板创新药行业集体业绩说明会。公司公告汇总海创药业股份有限公司将于2025年09月16日（星期二）15:00-17:00通过上海证券交易所上证路演中心举行2025年半年度科创板创新药行业集体业绩说明会，以网络文字互动形式与投资者交流公司经营成果及财务状况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091400001181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688302"],"gpt_icon":0},{"id":"2565548420","title":"每周股票复盘：海创药业（688302）氘恩扎鲁胺上市助营收增11899%","url":"https://stock-news.laohu8.com/highlight/detail?id=2565548420","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565548420?lang=zh_cn&edition=full","pubTime":"2025-09-07 04:08","pubTimestamp":1757189294,"startTime":"0","endTime":"0","summary":"截至2025年9月5日收盘，海创药业报收于58.28元，较上周的60.11元下跌3.04%。本周，海创药业9月2日盘中最高价报63.98元。减持后持股数量为4,875,780股，持股比例为4.9243%。公司公告汇总中信证券发布的2025年半年度持续督导跟踪报告显示，海创药业首个1类新药氘恩扎鲁胺软胶囊于2025年5月获批上市，实现销售收入1,306.88万元，营业收入同比增长11,899.08%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090700000795.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688302"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772139141329,"stockEarnings":[{"period":"1week","weight":-0.0244},{"period":"1month","weight":-0.0862},{"period":"3month","weight":-0.0803},{"period":"6month","weight":-0.268},{"period":"1year","weight":0.2447},{"period":"ytd","weight":-0.1051}],"compareEarnings":[{"period":"1week","weight":0.0158},{"period":"1month","weight":0.0016},{"period":"3month","weight":0.0664},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.2267},{"period":"ytd","weight":0.0448}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"海创药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"6815人(较上一季度增加3.97%)","perCapita":"14529股","listingDate":"2022-04-12","address":"四川省成都市武侯区高新区科园南路5号蓉药大厦1栋4层附2、3号","registeredCapital":"9901万元","survey":" 海创药业股份有限公司的主营业务是肿瘤、代谢性疾病等重大治疗领域的创新药物研发。公司的主要产品是HC-1119、HP518（PROTAC）、HP568（PROTAC）、HP537、HP560、HP501、HP515。公司荣获“2024年成都市企业技术中心”，“2024中国医药研发排行榜化药榜单前100强”，“成都市高新区“金熊猫未来星”·企业关键核心技术奖”等荣誉及称号。","listedPrice":42.92},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海创药业(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海创药业,688302,海创药业股票,海创药业股票老虎,海创药业股票老虎国际,海创药业行情,海创药业股票行情,海创药业股价,海创药业股市,海创药业股票价格,海创药业股票交易,海创药业股票购买,海创药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海创药业(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}